Kallikrein 7 Protein (KLK7) (His tag)

Catalog No. ABIN7196669

Product Details

Target: Kallikrein 7 (KLK7)

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: This Kallikrein 7 protein is labelled with His tag.

Purpose: Recombinant Human Kallikrein 7/KLK7 Protein (His Tag)(Active)

Sequence: Met 1-Arg 253

Characteristics: A DNA sequence encoding the human KLK7 (NP_005037.1) extracellular domain (Met 1-Arg 253) was expressed, with a C-terminal polyhistidine tag.

Purity: > 97 % as determined by reducing SDS-PAGE.

Endotoxin Level: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Measured by its ability to cleave the fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK (Dnp) NH2, R&D Systems, Catalog # ES002. The specific activity is >150 pmoles/min/μg.(Activation description: The proenzyme needs to be activated by Thermolysin for an activated form)

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Target Details

Target: Kallikrein 7 (KLK7)

Alternative Name: Kallikrein 7/KLK7 (KLK7 Products)

Synonyms: Prss6 Protein, SCCE Protein, PRSS6 Protein, hK7 Protein, kallikrein related-peptidase 7 (chymotryptic, stratum corneum) Protein, kallikrein-related peptidase 7 Protein, kallikrein related peptidase 7 Protein, Klk7 Protein, KLK7 Protein

Background:

Background: Kallikrein-7, also known as kallikrein-related peptidase 7, Stratum corneum chymotryptic enzyme, Serine protease 6, KLK7, and PRSS6, is a secreted protein which belongs to the peptidase S1 family and Kallikrein subfamily. Members of the Kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14). Kallikrein-7 / KLK7 appears to be increased in ovarian cancer and higher KLK7 expression in ovarian cancer tissue is associated with poorer prognosis of ovarian cancer patients. Kallikrein-7 / KLK7 is abundantly expressed in the skin and is expressed by keratinocytes in the epidermis. Kallikrein-7 / KLK7 is up-regulated in ovarian carcinoma, especially late-stage serous carcinoma, compared with normal ovaries and benign adenomas (at the protein level). It was significantly associated with shorter overall survival (OS) and disease-free survival (DFS). Kallikrein-7 / KLK7 may catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. KLK7 also plays a role in the activation of precursors to inflammatory cytokines.

Synonym: Kallikrein-7; hK7; Serine Protease 6; Stratum Corneum Chymotryptic Enzyme; hSCCE; KLK7; PRSS6; SCCE

Molecular Weight: 26.7 kDa

NCBI Accession: NP_005037

Pathways: Complement System